High-dose cytarabine improves outcome in patients with AML in EORTC-GIMEMA AML-12 Trial

December 19, 2013, European Organisation for Research and Treatment of Cancer

Results of the EORTC and GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia (AML). In particular, high-dose cytarabine produces higher remission and survival rates than the standard-dose cytarabine in patients younger than age 46 years old.

Dr. Roelof Willemze of the Leiden University Medical Centre and lead author of this report explains, "The most commonly administered induction regimen for with AML is a daily dose of 100 to 200 mg/m2 of cytarabine for seven to ten days in combination with three days of an anthracycline. This treatment has been shown to result in complete remission rates of 60% to 80% depending on age of the patient as well as genetic and molecular characteristics of the disease. Up until now, however, we did not have clear consensus on the benefit of higher dosages of cytarabine."

The AML-12 included 1,942 newly diagnosed patients with AML aged 15 to 60 years and compared remission induction treatment with daunorubicin, etoposide, and either standard-dose (100 mg/m2 per day by continuous infusion for 10 days) or high-dose (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7) cytarabine. Patients in complete remission received a single consolidation cycle containing daunorubicin and intermediate dose cytarabine.

At a median follow-up of six years, overall survival was 38.7% for patients receiving standard-dose and 42.5% for those receiving high-dose cytarabine (log-rank test P = 0.06; multivariable analysis P = 0.009).

For patients younger than 46 years old, survival was 43.3% with standard-dose treatment and 51.9% with high-dose treatment (P = 0.009; multivariable analysis P = 0.003). Survival for patients 46 to 60 years old was 33.9% and 32.9%, respectively (P = 0.91).

Complete remission rates were 72.0% for standard-dose and 78.7% for high-dose (P < 0.001). Patients younger than 46 years old had complete remission rates of 75.6% and 82.4%, respectively, (P = 0.01), while patients 46 years and older had rates of 68.3% and 74.8%, respectively (P = 0.03).

Explore further: Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial

Related Stories

Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial

October 22, 2013
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides ...

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

May 23, 2013
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

AML patients have high response rate with vorinostat added to treatment

December 13, 2011
Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center ...

Study finds genes improving survival with higher chemo doses in leukemia

March 14, 2012
New research published in the March 15 issue of the New England Journal of Medicine identifies gene mutations associated with improved overall survival with higher doses of chemotherapy for patients with acute myeloid leukemia ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.